Ponatinib Dose-Ranging Data in Chronic-Phase CML

Opinion
Video

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

CML_FO_Seg02_Ponatinib
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      A panel of 3 experts on CML
      When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
      A panel of 3 experts on CML
      Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
      A panel of 3 experts on CML
      Starting CML Treatment: Collaborative Choices for Better Outcomes
      Related Content
      Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

      HSCT Recipients Show Sustained Health Challenges Following Transplant

      Roman Fabbricatore
      March 25th 2025
      Article

      Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Elizabeth Shpall, MD
      May 29th 2019
      Podcast

      Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

      Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

      Highlighting Developments and Informing Treatment Planning in CLL Care

      Roman Fabbricatore
      March 13th 2025
      Article

      Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

      Immunotherapy Approaches in AML

      Immunotherapy Approaches in AML

      Naval Daver, MD
      January 17th 2019
      Podcast

      Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

      Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment

      Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment

      Ashley Chan
      February 15th 2025
      Article

      Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.

      The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.

      UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies

      Roman Fabbricatore
      February 13th 2025
      Article

      The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.